End-organ Disease and Inflammation Transformative Science Group

While most people living with HIV with access to antiretroviral therapy (ART) can now achieve and maintain viral suppression, there is a growing appreciation that ART does not restore normal health in most people living with HIV.  Compared to the general population, people living with HIV continue to have a shorter life expectancy and are at higher risk for several end organ diseases associated with the aging process (i.e., cardiovascular disease, osteoporosis, neurocognitive dysfunction, renal disease, etc.), and HIV-associated immune activation and inflammation appear to be strong predictors of this risk.

The End-organ Disease and Inflammation Transformative Science Group (ITSG) was created to foster collaborative efforts among virologists, immunologists, pharmacologists, and both clinical and laboratory researchers in the design of clinical trials of novel interventions targeting HIV-associated immune activation and inflammation, and/or end-organ diseases commonly associated with the aging process.  Observational studies evaluating the causes and consequences of HIV-associated immune activation using existing data and samples in the ACTG specimen repository are also conducted by this TSG.  We are also interested in studying other host targeted therapies designed to enhance immune recovery. Lastly, the ITSG conducts studies evaluating the influence of age and gender on the clinical consequences of HIV infection.